Cyclacel Pharmaceuticals to Host Conference Call to Review Sapacitabine Phase I Hematology Data on June 12, 2007.

BERKELEY HEIGHTS, N.J. -- Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) will host a conference call on June 12, 2007 at 11:00 am EDT to review interim results from its Phase I clinical trial of sapacitabine (CYC682) in patients with advanced leukemias or myelodysplastic syndromes (MDS). Spiro Rombotis, President and CEO, and Dr. Judy Chiao, VP of Clinical Development and Regulatory Affairs of Cyclacel, will be joined by the study's principal investigator, Dr. Hagop Kantarjian, Professor of Medicine and Chairman of the Leukemia Department at The University of Texas M. D. Anderson Cancer Center (UTMDACC) in Houston.

Conference Call Agenda:

* Introduction: Spiro Rombotis

* Review of Phase I Results: Dr. Judy Chiao

* Questions & Answers: Dr. Hagop Kantarjian and Dr. Judy Chiao

* Next steps for sapacitabine: Dr. Judy Chiao

* Closing Remarks: Spiro Rombotis

Conference call information:

US/Canada call: 888-603-6873; conference code 8841838

International call: 973-582-2706; conference code 8841838

Webcast: http://w.on24.com/r.htm?e=48695&s=1&k=24357A773AEF2611C82C3FE96B711D35 or via the Cyclacel Pharmaceuticals website at www.cyclacel.com.

The webcast will be archived for 90 days and the audio replay will be archived for 7 days. Access numbers for the audio replay are: 877-519-4471 (U.S./Canada) and 973-341-3080 (International); conference ID number is: 8841838.

About Sapacitabine

Sapacitabine appears to act through a dual mechanism. It interferes with DNA synthesis by causing single-strand DNA breaks and also induces arrest of cell cycle progression at G2/M-Phase. Both sapacitabine and CNDAC, its major metabolite or a substance into which the drugs converts after ingestion by patients, have demonstrated potent anti-tumor activity in preclinical studies. In addition, in a mouse model of liver metastasis, sapacitabine was shown to be superior in terms of delaying the onset and growth of liver metastasis to either gemcitabine (Gemzar[R]; Lilly) or 5-FU, two widely used nucleoside analogs. Gemcitabine is indicated for the palliative treatment of breast, lung, pancreatic and ovarian cancer, but it has not been reported to be active in leukemias or MDS.

A Phase II study of sapacitabine in patients with advanced cutaneous T cell lymphoma started in the first half of 2007. A second Phase II trial in hematological cancers is planned to begin later this year along with a third Phase II trial in patients with non-small cell lung cancer.

Sapacitabine is part of a deep pipeline of small molecule drugs designed to target and stop uncontrolled cell division. Cyclacel's other development programs include seliciclib, a CDK (cyclin dependent kinase) inhibitor in Phase IIb clinical trials for non-small cell lung cancer, and CYC116, an aurora kinase inhibitor in IND-directed development.

About Cyclacel Pharmaceuticals, Inc.

Cyclacel is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Two Cyclacel drugs are in Phase II trials: sapacitabine (CYC682), an orally-available, cell cycle modulating nucleoside analog, for the treatment of cutaneous T-cell lymphoma (CTCL) and seliciclib (CYC202), an orally-available CDK (cyclin dependent kinase) inhibitor, for the treatment of lung cancer. Sapacitabine is also in Phase I trials in patients with hematologic malignancies. CYC116, an orally-available, Aurora kinase and VEGFR2 inhibitor, is at the IND stage. Several additional programs are at an earlier stage.

Please visit http://www.cyclacel.com/cyc/investors/news/pressreleases for additional information.

Note: The Cyclacel logo and Cyclacel[R] are trademarks of Cyclacel Pharmaceuticals, Inc.

Risk Factors

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety, and intended utilization of Cyclacel's product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, the risk that Cyclacel will not obtain approval to market its products, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. These factors and others are more fully discussed under "Risk Factors" in the registration statement on Forms S-3 (File No. 333-134945) and S-4 (File No. 333-131225) and in the other reports of Cyclacel filed with the SEC.